Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

iPS-based cell lines focus of new Horizon deal
August 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, U.K.—Horizon Discovery Group plc has begun a collaboration with DefiniGEN Ltd. for the development of a range of unique, gene-engineered induced pluripotent stem (iPS)-based cell lines for use in research. Per the agreement, Horizon will conduct genome engineering on the iPS cells, which DefiniGEN will then differentiate. The initial focus will be on the generation of 10 iPS-based cell lines for research in areas with a lack of high-quality disease models. DefiniGEN will culture, differentiate and quality control the resulting cell lines, alongside an isogenic control, and the cell line reagents will be made available through DefiniGEN and co-marketed by Horizon.
 
Dr. Marcus Yeo, DefiniGEN’s CEO, noted that “These next-generation iPS cell products will help to improve the efficiency and economics of drug development and enable the underlying mechanisms of disease to be elucidated in a manner that has previously not been possible.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.